Serum levels of IgG antibodies against oxidized LDL and atherogenic indices in HIV-1-infected patients treated with protease inhibitors

Imagem de Miniatura
Arquivos
art_MARANHAO_Serum_levels_of_IgG_antibodies_against_oxidized_LDL_2013.PDF (3.01 MB)
Citações na Scopus
9
Tipo de produção
article
Data de publicação
2013
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
WALTER DE GRUYTER & CO
Autores
MASELLI, Luciana Morganti Ferreira
TREITINGER, Aricio
MONTEIRO, Andrea Moreira
GIDLUND, Magnus
SPADA, Celso
Citação
CLINICAL CHEMISTRY AND LABORATORY MEDICINE, v.51, n.2, p.371-378, 2013
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Background: Antibodies against low-density lipoproteins (LDLs) that have been oxidized are associated with development of atherosclerotic lesions. In individuals infected with human immunodeficiency virus type 1 (HIV-1) with or without therapy, dyslipidemia and increased cardiovascular risk are observed. Methods: Serum levels of IgG antibodies against oxidized LDLs (IgG anti-oxLDL Abs) were determined by assay in 151 HIV-1-infected patients. Of these, 42 patients did not receive anti-retroviral therapy (ART-naive), whereas 109 received highly active anti-retroviral therapy (HAART) consisting of lopinavir/ritonavir (LOP/r; n=50), efavirenz (EFV; n=30) and nevirapine (NVP; n=29) associated with nucleoside reverse transcriptase inhibitors. HIV-1 seronegative individuals (n=43) participated in the study. The following parameters were quantified: total cholesterol and its fractions, atherogenic indices (AIs), apolipoproteins A1 and B100, high sensitivity C-reactive protein, CD4(+) and CD8(+) T cells, and HIV-1-RNA. Results: Levels of IgG anti-oxLDL Abs were significantly higher (p<0.05) in the LOP/r group compared with the EFV and/or NVP and the seronegative group: median 0.32 (0.15, 0.58; 95% confidence interval) vs. 0.25 (0.13, 0.53) vs. 0.18 (0.04, 0.38), respectively. HIV-1-infected ART-naive patients (n=42) presented antibodies levels similar to those observed for the LOP/r group, 0.33 (0.13, 0.63; p>0.05). The levels of IgG anti-oxLDL Abs correlated with an increase in AIs (r=0.216; p=0.036) and triglycerides (r=0.220; p=0.044) in the LOP/r group, and AIs in the ART-naive group (r=0.300; p=0.046). Conclusions: Patients treated with LOP/r showed higher levels of IgG anti-oxLDL Abs compared with patients treated with EFV or NVP regimens, and these levels were associated with an increase in AIs.
Palavras-chave
atherogenic indices, highly active anti-retroviral therapy (HAART), HIV-1, IgG anti-oxidized low-density lipoprotein antibodies, protease inhibitors
URI
https://observatorio.fm.usp.br/handle/OPI/1770
Referências
  1. Brandao SA, 2010, AM J HYPERTENS, V23, P208, DOI 10.1038/ajh.2009.214
  2. CASTELLI WP, 1983, CIRCULATION, V67, P730
  3. Chaix C, 2000, J ACQ IMMUN DEF SYND, V24, P227
  4. Chang MK, 2002, P NATL ACAD SCI USA, V99, P13043, DOI 10.1073/pnas.192399699
  5. Chou MY, 2008, J INTERN MED, V263, P479, DOI 10.1111/j.1365-2796.2008.01968.x
  6. de Carvalho EH, 2010, METAB SYNDR RELAT D, V8, P403, DOI 10.1089/met.2009.0092
  7. Dragsted UB, 2003, J INFECT DIS, V188, P635, DOI 10.1086/377288
  8. Dube MP, 2008, CARDIOVASC TOXICOL, V8, P15, DOI 10.1007/s12012-007-9010-y
  9. Estrada V, 2011, BMC WOMENS HEALTH, V11, DOI 10.1186/1472-6874-11-36
  10. Faviou E, 2005, FREE RADICAL RES, V39, P419, DOI 10.1080/10715760500072156
  11. Fisac C, 2005, AIDS, V19, P917, DOI 10.1097/01.aids.0000171405.46113.bf
  12. FRIEDEWA.WT, 1972, CLIN CHEM, V18, P499
  13. Friis-Moller N, 2003, NEW ENGL J MED, V349, P1993
  14. Grinspoon S, 2005, NEW ENGL J MED, V352, P48, DOI 10.1056/NEJMra041811
  15. Hui DY, 2003, PROG LIPID RES, V42, P81, DOI 10.1016/S0163-7827(02)00046-2
  16. Itabe H, 2009, CLIN REV ALLERG IMMU, V37, P4, DOI 10.1007/s12016-008-8095-9
  17. Kadar A, 2001, CARDIOVASC SURG, V9, P109, DOI 10.1016/S0967-2109(00)00097-1
  18. Laczik R, 2011, LUPUS, V20, P730, DOI 10.1177/0961203311398884
  19. Lalezari JP, 2003, NEW ENGL J MED, V348, P2175, DOI 10.1056/NEJMoa035026
  20. Mary-Krause M, 2003, AIDS, V17, P2479, DOI 10.1097/00002030-200311210-00010
  21. Matsuura E, 2008, AUTOIMMUN REV, V7, P558, DOI 10.1016/j.autrev.2008.04.018
  22. Medeiros AMB, 2010, ARQ BRAS CARDIOL, V95, P47, DOI 10.1590/S0066-782X2010005000063
  23. Millán Jesús, 2009, Vasc Health Risk Manag, V5, P757
  24. Navab M, 2004, J LIPID RES, V45, P993, DOI 10.1194/jlr.R400001-JLR200
  25. Negredo E, 2004, ANTIVIR THER, V9, P889
  26. Panel on Anti-retroviral Guidelines for Adults and Adolescents, 2009, MMWR RECOMM REP, P1
  27. Parra S, 2010, J INFECT DIS, V201, P627, DOI 10.1086/650312
  28. Pereira SA, 2006, BRIT J CLIN PHARMACO, V61, P601, DOI 10.1111/j.1365-2125.2006.02619.x
  29. Petit JM, 2003, J LIPID RES, V44, P1692, DOI 10.1194/jlr.M300041-JLR200
  30. Riddler SA, 2008, JAIDS-J ACQ IMM DEF, V48, P281, DOI 10.1097/QAI.0b013e31817bbbf0
  31. Rose H, 2008, ATHEROSCLEROSIS, V199, P79, DOI 10.1016/j.atherosclerosis.2007.10.018
  32. Sankatsing RR, 2009, ATHEROSCLEROSIS, V202, P589, DOI 10.1016/j.atherosclerosis.2008.05.028
  33. SHORPOSNER G, 1993, AM J MED, V94, P515, DOI 10.1016/0002-9343(93)90087-6
  34. Stocker R, 2004, PHYSIOL REV, V84, P1381, DOI 10.1152/physrev.00047.2003
  35. Suzuki K, 2004, CANCER EPIDEM BIOMAR, V13, P1781
  36. Tarr PE, 2010, PHARMACOGENOMICS, V11, P587, DOI [10.2217/pgs.10.35, 10.2217/PGS.10.35]
  37. Tashima KT, 2003, HIV CLIN TRIALS, V4, P29
  38. Thompson MA, 2010, JAMA-J AM MED ASSOC, V304, P321, DOI 10.1001/jama.2010.1004
  39. Wang XW, 2007, JAIDS-J ACQ IMM DEF, V44, P493, DOI 10.1097/QAI.0b013e3180322542
  40. Wohl D, 2008, JAIDS-J ACQ IMM DEF, V48, P44, DOI 10.1097/QAI.0b013e31816d9ba1

Coleções
Artigos e Materiais de Revistas Científicas - FM/MCM
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - HC/InCor
Artigos e Materiais de Revistas Científicas - LIM/31
Artigos e Materiais de Revistas Científicas - ODS/03